Skip to main content
Premium Trial:

Request an Annual Quote

DNA2.0, Operon Biotechnologies Pen Co-Marketing Alliance

NEW YORK (GenomeWeb News) — Synthetic gene company DNA2.0 and oligonucleotide synthesis shop Operon Biotechnologies today said they have formed a co-marketing alliance.
 
Terms of the deal call for Operon to co-market DNA2.0’s gene-synthesis services, while Operon’s oligos will become the “primary source” of the oligos that go into DNA2.0’s synthetic genes, the companies said.
 
The companies are betting that the alliance will increase DNA2.0's speed of synthesis and give Operon access to what the firms call “the fastest growing application area for oligonucleotides today.”
 
Financial terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.